Raptor Pharmaceutical Corp Form 3 October 03, 2014

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Ad Person * Hyperion Portfolio		gregated (	2. Date of Evo Statement Month/Day/1 11/20/2012		3. Issuer Nar Raptor Ph				
(Last)	(First)	(Middle)			4. Relationsh Person(s) to		1 0	5	5. If Amendment, Date Original Filed(Month/Day/Year)
C/O TMF LT PAVILLION CTR, 2ND BAY ROAD	COMM. FL., 802 W	VEST			(Check	or	applicable)  _X 10%  Other (specify below)	Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
GRAND CAYMAN,Â	E9Â KY1	-1003							_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)		Table I - N	Non-Deriva	tive	e Securiti	es Bei	neficially Owned
1.Title of Securi (Instr. 4)	ity			2. Amount of Beneficially (Instr. 4)		Fo D on (I	ownership orm: birect (D) r Indirect	4. Nat Owner (Instr.	*
Common Sto	ck, par valı	ue \$0.001 pe	er share (1)	5,176,500			D	Â	
Reminder: Repo		te line for each	class of secu	ırities benefici	ally	SEC	1473 (7-02	)	
	informa require	ns who respond ation contained to respond tly valid OME	ned in this f d unless the	orm are not e form displa					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date

3. Title and Amount of Securities Underlying

4. S. 6. Nature of Indirect Conversion Ownership

# Edgar Filing: Raptor Pharmaceutical Corp - Form 3

	(Month/Day/Year)		Derivative Se (Instr. 4)	ecurity	or Exercise Price of	Form of Derivative	(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Contracts for Difference (2)	(2)	(2)	Common Stock	1,000	\$ 5.29 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	1,000	\$ 5.27 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	1,000	\$ 5.29 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	1,000	\$ 5.27 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	2,000	\$ 5.28 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	1,345	\$ 5.25 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	2,000	\$ 5.25 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	10,000	\$ 5.24 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	10,000	\$ 5.29 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	4,000	\$ 5.31 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	4,000	\$ 5.31 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	4,000	\$ 5.31 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	4,000	\$ 5.31 (2)	D	Â	
Contracts for Difference $\underline{^{(2)}}$	(2)	(2)	Common Stock	10,000	\$ 5.29 (2)	D	Â	
Contracts for Difference $\underline{^{(2)}}$	(2)	(2)	Common Stock	22,500	\$ 5.3 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	4,000	\$ 5.26 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	4,000	\$ 5.26 (2)	D	Â	
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.23 (2)	D	Â	

### Edgar Filing: Raptor Pharmaceutical Corp - Form 3

Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.24 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.25 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.24 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.25 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.24 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.23 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.2 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,245	\$ 5.2 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	10,000	\$ 5.2 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	10,000	\$ 5.2 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	120	\$ 5.19 (2)	D	Â
Contracts for Difference (2)	(2)	(2)	Common Stock	2,200	\$ 5.19 (2)	D	Â

# **Reporting Owners**

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			

Hyperion Trading Segregated Portfolio C/O TMF LTD. GRAND PAVILLION COMM. CTR 2ND FL., 802 WEST BAY ROAD, PO BOX 10338 GRAND CAYMAN, E9Â KY1-1003

### Â X Â Â

### **Signatures**

/s/ David P.M. Blair and Richard A. Reinert

08/19/2014

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Reporting Owners 3

#### Edgar Filing: Raptor Pharmaceutical Corp - Form 3

The shares of common stock, \$0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Star Arrow Funds Expertise Ltd, a company organized under the laws of Anguilla ("Star").

On November 20, 2012, the Reporting Person held Contracts for Difference of the Common Shares (the "CFDs") reported herein with a securities broker (the "Issuer of the CFDs"), upon which, pursuant to an agreement between the Reporting Person and the Issuer of the CFDs, upon conversion of the CFDs (i) the Issuer of the CFDs would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion, the Reporting Person would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion, the Reporting Person would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion. As of November 20, 2012, the Reporting Person and the Issuer of the CFDs had not converted any of the CFDs.

#### Â

#### **Remarks:**

1. Â The Common Shares and CFDs reported herein represent securities (the "Securities") held by th Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.